BrainStorm Announces Operational Highlights and Financial Results for the Year Ended December 31, 2017

Conference Call and Webcast @ 8:30 a.m. Eastern Time Today NEW YORK and PETACH TIKVAH, Israel, March 8, 2018 -- (Healthcare Sales &Marketing Network) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technolog... Regenerative Medicine, Neurology BrainStorm Cell Therapeutics, NurOwn , stem cell, amyotrophic lateral sclerosis
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news

Related Links:

Abstract Age-related neurological disorders continue to pose a significant societal and economic burden. Aging is a complex phenomenon that affects many aspects of the human body. Specifically, aging can have detrimental effects on the progression of brain diseases and endogenous stem cells. Stem cell therapies possess promising potential to mitigate the neurological symptoms of such diseases. However, aging presents a major obstacle for maximum efficacy of these treatments. In this review, we discuss current preclinical and clinical literature to highlight the interactions between aging, stem cell therapy, and th...
Source: Neurobiology of Disease - Category: Neurology Authors: Tags: Neurobiol Dis Source Type: research
Authors: Khairoalsindi OA, Abuzinadah AR Abstract Amyotrophic lateral sclerosis is a neurodegenerative disease that leads to loss of the upper and lower motor neurons. Almost 90% of all cases occur in the sporadic form, with the rest occurring in the familial form. The disease has a poor prognosis, with only two disease-modifying drugs approved by the United States Food and Drug Administration (FDA). The approved drugs for the disease have very limited survival benefits. Edaravone is a new FDA-approved medication that may slow the disease progression by 33% in a selected subgroup of ALS patients. This paper covers ...
Source: Neurology Research International - Category: Neurology Tags: Neurol Res Int Source Type: research
Purpose of review This review analyses the recent efforts to develop therapeutics using transplantation of stem cells for amyotrophic lateral sclerosis (ALS). Recent findings Stem cells are considered as a potential therapeutic for a variety of neurodegenerative diseases, in an effort to either replace cells that are lost, or to enhance the survival of the remaining cells. In ALS, meaningful attempts to verify the safety and feasibility of many cell transplantation approaches have only recently been completed or are underway. Due to the complexities of reconstructing complete motor neuron circuits in adult patients, c...
Source: Current Opinion in Neurology - Category: Neurology Tags: MOTOR NEURON DISEASE: Edited by Jeremy Shefner and Shafeeq S. Ladha Source Type: research
Publication date: 28 August 2018Source: Cell Reports, Volume 24, Issue 9Author(s): Erin L. Slosarek, Amber L. Schuh, Iryna Pustova, Adam Johnson, Jennifer Bird, Matthew Johnson, E.B. Frankel, Nilakshee Bhattacharya, Michael G. Hanna, Jordan E. Burke, David A. Ruhl, Kyle Quinney, Samuel Block, Jennifer L. Peotter, Edwin R. Chapman, Michael D. Sheets, Samuel E. Butcher, Scott M. Stagg, Anjon AudhyaSummaryLength-dependent axonopathy of the corticospinal tract causes lower limb spasticity and is characteristic of several neurological disorders, including hereditary spastic paraplegia (HSP) and amyotrophic lateral sclerosis. Mu...
Source: Cell Reports - Category: Cytology Source Type: research
Amyotrophic lateral sclerosis (ALS), the most common degenerative disease affecting motor neurons, lacks an effective disease-modifying disease treatment [1 –3]. Recently, the Src/c-Abl pathway has been postulated as a potential therapeutic target in ALS. [4]. Imamura et al. developed a phenotypic screen to repurpose existing drugs for ALS patients, which resulted in the identification of 27 potential hits. Intriguingly, more than half of the hits tar geted the Src/c-Abl signaling pathway [4]. Complementary studies demonstrated that Src/c-Abl inhibitors increased the survival of induced pluripotent stem cells (iPSC)-...
Source: Journal of the Neurological Sciences - Category: Neurology Authors: Tags: Letter to the Editor Source Type: research
AbstractMany  central nervous system diseases currently lack effective treatment and are often associated with defects in microvascular function, including a failure to match the energy supplied by the blood to the energy used on neuronal computation, or a breakdown of the blood–brain barrier. Pericytes, an u nder-studied cell type located on capillaries, are of crucial importance in regulating diverse microvascular functions, such as angiogenesis, the blood–brain barrier, capillary blood flow and the movement of immune cells into the brain. They also form part of the “glial” scar isolating dam...
Source: Acta Neuropathologica - Category: Neurology Source Type: research
Volume 18, Issue 8, August 2018, Page 865-881 .
Source: Expert Opinion on Biological Therapy - Category: Drugs & Pharmacology Authors: Source Type: research
Annals of Neurology,Volume 0, Issue ja, -Not available-.
Source: Annals of Neurology - Category: Neurology Authors: Source Type: research
Authors: Walker LC, Meadows MR, Du Y, March LK, Jones JK Abstract BACKGROUND: Amyotrophic lateral sclerosis (ALS) is devastating, leading to paralysis and death. Disease onset begins pre-symptomatically through spinal motor neuron (MN) axon die-back from musculature at ∼47 days of age in the mutant superoxide dismutase 1 (mSOD1G93A) transgenic ALS mouse model. This period may be optimal to assess potential therapies. We previously demonstrated that post-symptomatic adipose-derived stem cell conditioned medium (ASC-CM) treatment is neuroprotective in mSOD1G93A mice. We hypothesized that early disease onset treat...
Source: Restorative Neurology and Neuroscience - Category: Neurology Tags: Restor Neurol Neurosci Source Type: research
Publication date: Available online 22 April 2018Source: Journal of Clinical Orthopaedics and TraumaAuthor(s): Manoj Kumar, Sanjeev Bhoi, Keshava SharmaAbstractHematopoietic failure (HF) has been observed in trauma hemorrhagic shock (T/HS) patients. Multiple factors are involved. Elevated serum levels of cytokines, catecholamine, granulocyte colony stimulating factor, peripheral blood hematopoietic progenitor cells (HPCs) and decreased expression of erythropoietin receptor are associated with HF among T/HS. HF leads to anaemia, susceptibility to infection, sepsis and multi-organ failure. There is a lack of molecular underst...
Source: Journal of Clinical Orthopaedics and Trauma - Category: Orthopaedics Source Type: research
More News: ALS | Brain | Conferences | Israel Health | Marketing | Middle East Health | Neurology | Pharmaceuticals | Stem Cell Therapy | Stem Cells